I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
Myeloproliferative Disorders, Leukemia
About this trial
This is an interventional supportive care trial for Myeloproliferative Disorders focused on measuring Myeloproliferative Disorders, Leukemia
Eligibility Criteria
Inclusion Criteria: -≥18 years of age Diagnosed with an MPN by WHO 2016 criteria,22 including essential thrombocythemia (ET), polycythemia vera (PV), prefibrotic myelofibrosis (pre-MF), myelofibrosis (MF), and MPN not otherwise specified (NOS). Within MF patients, only patients who are low or intermediate-1 risk by the Dynamic International Prognostic Scoring System (DIPSS) are eligible.23 All risk groups are eligible for the remaining MPN subtypes. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 Must have at least one cardiovascular risk factor including: Body mass index (BMI) >25 kg/m2, hypertension, hyperlipidemia, diabetes mellitus or pre-diabetes or metabolic syndrome, or any prior history of cardiovascular disease, transient ischemic attack, stroke, or peripheral vascular disease. Patients not meeting any cardiovascular risk criteria must receive prior approval from the PI to participate in this study. Exclusion Criteria: -- MF patients with intermediate-2 or high-risk disease by DIPSS ECOG performance status >2. Any injury or medical condition that would prohibit being able to safely perform exercise, as determined by the treating physician.
Sites / Locations
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
- Massachusetts General Hospital Cancer Center
Arms of the Study
Arm 1
Experimental
Cardiac Lifestyle Program
Participants will complete study procedures as follows: Baseline in-clinic visit with research team doctor for history and physical and the completion of questionnaires. 6 virtual group classes alternating with 6 in-person group classes. Semi-structured exit interview.